MESOBLAST LTD (MESO) Form 6-K — Oct 29, 2026
Mesoblast reported US$28 million in RYONCIL net revenue for the quarter ended September 30, 2026, a 44% increase over the prior year period, with September delivering the highest number of new patient starts for the month. The company cut net operating cash spend 86% to US$2.1 million and ended the quarter with US$98.5 million in cash, implying roughly 46 quarters of funding at the current burn rate — though it carries a fully drawn US$125 million facility at 8.00% held by an existing shareholder and director.
Key figures
- Revenue
- 28000000
- Debt Amount
- 125000000
- Revenue Yoy
- 44% increase
- Cash Position
- 98545000
- Interest Rate
- 8
- Granted patents
- over 1,000
- Adult sr agvhd trial sites
- up to 40 US sites
- Phase3 clbp trial enrollment
- 350
- Estimated quarters of funding
- 46.3
- Prior year operating cash spend
- US$14.9 million
- Us adult bmt population addressed
- ~60% of ~8,500 annual
- Net operating cash spend q1 fy2027
- US$2.1 million
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.